

# Technical Report No. 47

## Preparation of Virus Spikes Used for Virus Clearance Studies



**2010**

## **Preparation of Virus Spikes Used for Virus Clearance Studies Task Force**

---

### **Authors**

**Damon Asher**, PhD, Millipore Corp.

**Kurt Brorson**, PhD, U.S. Food and Drug Administration

**JoAnn Hotta**, Talecris Biotherapeutics

**Joseph Hughes**, PhD, WuXi AppTec, Inc.

**Jerold Martin**, Pall Life Sciences

**Horst Ruppach**, NewLab BioQuality GmbH

**Gail Sofer**, SofoWare Associates

**Martin Wisher**, PhD, BioReliance, Inc.

**Hannelore Willkommen**, PhD, RBS-Consulting

**Bin Yang**, PhD, Genentech, Inc.

### **Contributors**

**Mark Bailey**, Eli Lilly and Company

**Kate Bergman**, Lancaster Labs.

**Johannes Blümel**, PhD, Paul-Ehrlich Institut

**Jeri Anne Boose**, Compliance Insight, Inc.

**Mark Cabatingan**, Hoffmann- La Roche Inc.

**Dayue Chen**, PhD, Eli Lilly and Company

**Qi Chen**, PhD, Genentech, Inc.

**Michael Colman**, Millipore Corp.

**Michelle Davis**, Talecris Biotherapeutics

**Frank van Engelenburg**, Kinesis Pharma

**Charles Felice**, Centocor Ortho Biotech (Johnson and Johnson)

**Ren-yo Forng**, PhD, MedImmune, Inc.

**Albrecht Gröner**, CSL Behring GmbH

**Mohammed Haque**, Pall Life Sciences

**Arifa Khan**, PhD, U.S. Food and Drug Administration

**Richard Levy**, PhD, PDA

**Scott Lute**, U.S. Food and Drug Administration

**Carol Marcus-Sekura**, BASI

**Michael Morgan**, Asashi Kasei, Planova Division

**Masahiro Oda**, Pall Life Sciences

**Leonard Pease**, PhD, University of Utah

**Kathy Remington**, PhD, Catalent Pharma Solutions, Inc

**Barry Rosenblatt**, Charles River Labs.

**Michael Ruffing**, PhD, Boehringer Ingelheim

**Fokke Terpstra**, Sanquin NL

**Ruth Wolff**, Biologics Consulting Group

The content and views expressed in this Technical Report are the result of a consensus achieved by the Task Force and are not necessarily views of the organizations they represent or regulatory authorities in the E.U. or the U.S. Government.

# **Preparation of Virus Spikes Used for Virus Clearance Studies**

**Technical Report No. 47**

ISBN: 978-0-939459-27-8

© 2010 Parenteral Drug Association, Inc.

All rights reserved.





## Table of Contents

<b>1.0 INTRODUCTION.....</b>	<b>4</b>		
<b>2.0 GLOSSARY OF TERMS.....</b>	<b>6</b>		
<b>3.0 PREPARATION OF VIRUS STOCKS .....</b>	<b>10</b>		
3.1 Introduction.....	10		
3.2 Sourcing of Viruses and Preparation of Virus...	10		
3.2.1 Viruses Used for Viral Clearance Studies ..	10		
3.3 Sourcing and Traceability of Viruses.....	12		
3.3.1 Traceability of Viruses.....	12		
3.4 Preparation of Virus Seed .....	13		
3.4.1 Approaches for Preparation .....	13		
3.4.2 Virus Seed Preparation .....	14		
3.5 Preparation of Master and Working Virus Banks .....	14		
3.5.1 Preparation of the Master Virus Bank (MVB).....	15		
3.5.2 Preparation of the Working Virus Bank (WVB) .....	16		
3.6 Preparation of Virus Used for Virus Clearance Studies.....	16		
3.6.1 Cytopathic Viruses.....	16		
3.6.2 Non-cytopathic Viruses .....	17		
3.7 Storage of Virus Stocks.....	17		
3.8 Purification of Viruses.....	18		
3.8.1 Purification by Ultracentrifugation .....	18		
3.8.1.1 Pelleting.....	18		
3.8.1.2 Cushions.....	18		
3.8.1.3 Gradient Ultracentrifugation.....	19		
3.8.2 Purification by Membrane Adsorber .....	19		
3.8.2.1 Purification of Parvoviruses on a Q Membrane Adsorber.....	19		
3.9 Methods Used to Reduce Aggregates.....	20		
3.9.1 Filtration .....	20		
3.9.2 Filtration at the Spiking Step .....	21		
3.9.3 Sonication .....	22		
<b>4.0 METHODS FOR CHARACTERIZATION .....</b>	<b>23</b>		
4.1 Identity Testing.....	23		
4.1.1 Sequencing.....	23		
4.1.2 Immunological Assays.....	23		
4.2 Functional Properties.....	24		
4.2.1 Infectivity Assays.....	24		
4.2.1.1 Data Analyses and Validation of Methods for Virus Enumeration .....	24		
4.2.2 Total Particle Count.....	24		
4.2.2.1 Electron Microscopic Determinations .....	24		
4.2.2.2 Quantitative PCR .....	25		
4.2.2.3 Spectrophotometric Measurement.....	25		
4.2.2.4 Infectivity to Particle Ratio.....	25		
4.2.3 Aggregation.....	26		
4.2.3.1 Dynamic Light Scattering (DLS).....	26		
4.2.3.2 Filter Sizing.....	26		
4.2.3.3 Newer Methods .....	26		
4.3 Purity.....	26		
4.3.1 Protein Content.....	26		
4.3.2 DNA/RNA Content .....	27		
4.4 Contamination .....	28		
4.4.1 Sterility/Bioburden.....	28		
4.4.2 Mycoplasma.....	28		
4.4.3 Adventitious Viruses.....	29		
4.4.3.1 <i>In vitro</i> assays .....	29		
4.4.3.2 Immunoassays .....	29		
<b>5.0 IMPACT OF VIRUS SPIKE ON THE SCALED DOWN MODEL AND ON VIRUS REMOVAL AND INACTIVATION.....</b>	<b>30</b>		
5.1 Introduction.....	30		
5.2 Influence of the Virus Spike on the Scaled Down Model .....	30		
5.2.1 Chromatography .....	30		
5.2.2 Filtration .....	31		
5.2.2.1 Filtration Case Study #1 .....	31		
5.2.2.2 Filtration Case Study #2 .....	32		
5.2.2.3 Filtration Case Study #3 .....	33		
5.2.2.4 Filtration Case Study #4 .....	34		
5.3 Influence of the Virus Spike on the Log <sub>10</sub> Reduction Value (LRV) .....	35		
5.3.1 Chromatography .....	36		
5.3.2 Filtration .....	36		
5.3.2.1 Filtration Case Study #5 .....	37		
5.3.2.2 Filtration Case Study #6 .....	37		
5.3.2.3 Filtration Case Study #7 .....	39		
5.3.2.4 Filtration Case Study #8 .....	40		
5.4 Influence of Virus Spike on Inactivation.....	43		
5.4.1 Inactivation Case Study #1 (Pasteurization).....	43		
5.4.2 Inactivation Case Study #2 (Extreme pH) .....	44		
5.4.3 Inactivation Case Study #3 (Low pH).....	44		
<b>6.0 PHAGE PREPARATIONS FOR SPIKING STUDIES.....</b>	<b>46</b>		
6.1 Typical Use of Phages in Spiking Studies .....	46		
6.2 Potential Phage Models.....	46		
6.2.1 PR772.....	46		

6.2.2	Φ6 .....	47	7.3.2	Cultivation and Storage of Cells .....	53
6.2.3	ΦX-174.....	47	7.3.2.1	Medium Components .....	53
6.2.4	PP7 .....	47	7.3.2.2	Serum.....	54
6.2.5	MS2.....	48	7.3.2.3	Trypsin.....	55
<b>7.0</b>	<b>CONTROL OF CELLS USED FOR VIRUS</b>		7.3.3	Cryopreservation and Storage .....	55
	<b>PROPAGATION AND TITRATION .....</b>	<b>51</b>	7.4	Cell Bank Testing .....	55
7.1	Introduction .....	51	7.5	Cell Line Characterization .....	56
7.2	Origin, Source, and History of Cells .....	51	7.6	Raw Material Sourcing and Preparation .....	58
7.3	Preparation of Cells and Cell Banking .....	52	7.7	Documentation .....	59
7.3.1	Preparation of Master Cell Bank (MCB) and Working Cell Bank (WCB) .....	52	<b>8.0</b>	<b>REFERENCES.....</b>	<b>61</b>

## FIGURES AND TABLES INDEX

<b>Table 3.2.1</b>	Mammalian Viruses Used in Virus Validation Studies.....	11	<b>Figure 5.3.2.2-2</b>	LRV Of PPV Using PPV Preparations of Different Purity .....	39
<b>Figure 3.5</b>	Master and Working Virus Bank Preparation Flowchart.....	15	<b>Figure 5.3.2.3</b>	Reduced LRV Observed with Flow Decay in a Small Virus Retentive Filter Caused by High Molecular Weight DNA .....	40
<b>Table 3.7</b>	Stability of SV40 and MMV Stored at -80°C.....	18	<b>Figure 5.3.2.4-1</b>	Purification of X-MuLV and MMV by Sucrose Gradient Centrifugation .....	41
<b>Figure 3.8.2.1</b>	Chromatograph of PPV Purified on a Q Membrane Adsorber .....	20	<b>Figure 5.3.2.4-2</b>	SV40 Stock Purification and Analysis .....	41
<b>Table 3.8.2.1</b>	Purification of PPV on a Q Membrane Adsorber.....	20	<b>Table 5.3.2.4</b>	SV40 Clearance by a Large Retentive Virus Filter .....	42
<b>Table 3.9.2</b>	Reduction of Virus Titer after Spiking and Pre-Filtration Through 0.2 and 0.1 $\mu$ m Rated Filters.....	21	<b>Table 5.3.2.5</b>	Effect of pH and Spike Quality on Observed LRV of PPV with a Large Virus Filter .....	42
<b>Figure 4.1.2</b>	Porcine parvovirus Infected Cultures of ST Cells; Uninfected Cells .....	23	<b>Table 5.3.2.6</b>	Removal of Virus Aggregates by Filtration.....	43
<b>Table 4.3.1</b>	Protein Concentration of MMV Purified by Various Means.....	27	<b>Figure 5.4.1</b>	Inactivation of Different HAV Preparations by Pasteurization in Albumin.....	44
<b>Table 5.2.1</b>	Product Yield from Four Scaled-Down Unit Operations Using Different Spike Ratios.....	31	<b>Figure 5.4.2</b>	Inactivation of Different HAV Preparations by Extreme pH.....	44
<b>Figure 5.2.2.1</b>	HAV Retention by a Small Size Virus Retentive Filter Using Different Spike Ratios.....	32	<b>Figure 5.4.5</b>	Inactivation of Different BVDV Preparations by Low pH.....	45
<b>Figure 5.2.2.2</b>	Capacity of a Virus Filter in Relation to the Purity of the Virus Spike.....	33	<b>Table 6.2</b>	Summary of the Properties of Selected Bacteriophages .....	47
<b>Figure 5.2.2.3</b>	Flow Decay in a Small Virus Filter Caused by High Molecular Weight Mammalian DNA .....	34	<b>Figure 6.3</b>	Procedure for Growth and Purification of Bacteriophages .....	50
<b>Figure 5.2.2.4</b>	Effect Of Spike Purity on Throughput of Various Small Virus Filters.....	35	<b>Figure 7.3.1</b>	Morphology of Vero Cells in Different Growth Stages.....	53
<b>Figure 5.3.1</b>	Influence of Spike Purity on LRV by a Small Virus Retentive Filter .....	36	<b>Figure 7.5-1</b>	Examples Demonstrating the Susceptibility of Two Cell Lines to Various Viruses .....	57
<b>Figure 5.3.2.1</b>	Small Virus Filter LRV Observed with Purified and Crude MMV Preparations.....	37	<b>Figure 7.5-2</b>	Virus Growth Characteristic (HAV, Strain HM175, in FRHK-4 Cells) .....	58
<b>Figure 5.3.2.2-1</b>	Filtration Volume Of Spiked IgG Using Different PPV Preparations ...	38	<b>Table 7.7</b>	Documentation for Cell Banks and the Use of Cells .....	60

## 1.0 Introduction

Assuring the viral safety of plasma derived biologicals and biopharmaceuticals is critical for safe use by healthcare consumers and successful marketing by industry of these vitally important healthcare products. Incidences of contamination of products derived from human plasma in the past have adversely impacted the health of hundreds of patients and tainted the image of certain segments of the healthcare industry. Today's recombinant biopharmaceuticals have never, as far as we know, presented a similar viral safety issue, and plasma derived products have a better safety record today. This is in large part due to stringent measures taken by the industry and regulators to mitigate viral safety risks.

The current strategy for ensuring viral safety involves multiple levels of control over the product and process, including cell bank screening, source material screening and/or inactivation, and incorporation of specific virus removal or inactivation steps into the production scheme. Validating the ability of the process to remove or inactivate viruses is key in understanding the ability of the manufacturing scheme to clear viruses, in the unlikely event that they do contaminate a process intermediate, and in providing a yard-stick to determine if the clearance capacity is large enough to assure viral safety.

Viral clearance studies start by designing scale-down models of the actual manufacturing unit operations. The objective of the scale-down model is to determine the performance and viral clearance that can be expected of a unit operation at full scale. First, key and critical process parameters, as defined in PDA Technical Report No. 42 (1) or ICH Q8(R2) (2) (e.g., resin contact time, filtration volume per membrane surface), are matched between the scale-down models and commercial large scale processing. Second, key and critical performance parameters, such as step yield and purity, must be representative of the large scale unit operation. Non-key/non-critical operating parameters, like column bed diameter and filter area, are lowered to allow reduction of the model unit operation to a scale practical for lab studies. Other key and critical parameters have to be considered if precipitation steps are investigated and virus is removed by distribution into the precipitate.

Viral clearance studies are conducted by spiking virus into the relevant intermediate and processing the spiked material in a scaled down unit operation. The reduction in the virus load by the unit operation demonstrates the effectiveness of the process step for virus removal or inactivation. The virus spike used in viral clearance studies should be representative of a potential contaminant to the extent achievable. Not only is the selection of appropriate relevant or model viruses important; the properties of the virus spike must also be considered. For example, the presence of serum in a virus spike may be problematic for a validation study of a serum-free manufacturing scheme. As another example, the presence of non-viral extraneous macromolecules, such as proteins and DNA, would be problematic for a validation of a downstream unit operation where the process fluid is presumably a highly purified, non-aggregated protein. It is important that contaminants in the virus spike itself do not impact key or critical performance parameters in a way that makes the scale-down model unrepresentative of the large scale process.

Achievement of these goals involves careful selection and design of virus spikes, both in terms of volume of spiking and purity of the preparations themselves. While it is relatively straightforward to modify the spiking volume to the point where it is non-interfering, achievement of spike purity is more complicated. Presently, some relatively crude spikes are produced directly from unprocessed clarified cell culture lysates or culture supernatants for direct use in validation studies. These spikes, like most biological systems, are relatively heterogeneous and difficult to control. Other virus preparations that are purified by ultracentrifugation/re-suspension, chromatography or other methods possess higher purity, but are still heterogeneous to some degree. The heterogeneities and